The Central Drugs Standard Control Organization (CDSCO) has invited public comments on a proposal regarding the use of brand name extensions by pharmaceutical companies. The consultation follows recommendations of the Drugs Consultative Committee (DCC), which raised concerns that similar brand names with different active ingredients may confuse consumers. Stakeholders can submit their comments to CDSCO by 17 July 2026 to support the regulatory review process.
The Central Drugs Standard Control Organization (CDSCO) has issued a notice inviting public comments on the proposed regulatory approach for the use of brand name extensions by pharmaceutical companies.
The proposal follows discussions held during the 67th Drugs Consultative Committee (DCC) meeting after concerns were raised regarding the marketing of different drug formulations under the same established brand name with different extensions. CDSCO has initiated stakeholder consultation to gather feedback before considering further regulatory action.
Key highlights of the notice include:
- Public consultation on the use of brand name extensions in pharmaceutical products.
- Concerns that similar brand names with different active ingredients may confuse consumers regarding therapeutic use.
- Recommendations of the Drugs Consultative Committee have been published on the CDSCO website.
- Stakeholders may submit comments to CDSCO by 17 July 2026.
- Feedback received will support future regulatory decisions on the matter.
The consultation aims to improve clarity in pharmaceutical branding and promote the safe use of medicines.